Viking Therapeutics Stock Climbs On Q2 EPS Beat
Portfolio Pulse from Erica Kollmann
Viking Therapeutics (NASDAQ:VKTX) shares surged after the company reported better-than-expected Q2 financial results. The company posted a loss of 20 cents per share, beating the analyst consensus of 27 cents per share. Despite an increased net loss due to higher R&D and administrative expenses, the stock rose 10.10% in after-hours trading.
July 24, 2024 | 9:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics reported a Q2 loss of 20 cents per share, beating the analyst consensus of 27 cents per share. Despite an increased net loss due to higher R&D and administrative expenses, the stock rose 10.10% in after-hours trading.
The better-than-expected EPS indicates strong financial performance, which is a positive signal for investors. The stock's 10.10% rise in after-hours trading reflects market optimism. However, the increased net loss due to higher R&D and administrative expenses could be a concern for long-term profitability.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100